A gene-editing drug developed by CRISPR Therapeutics and Vertex Pharma has achieved “remarkable” improvements in patients with beta thalassaemia and sickle cell disease in an early-stage trial ...

There's a new player on the antibody-drug conjugate (ADC) scene. UK-based Pheon Therapeutics has entered stage right with $68 million in funding that will be used to fund development of a pipeline of ...